Glycoprotein Ib-regulated micro platelet ghost for biosafe distribution and photothermal oncotherapy

Zou, Jiahui; He, Jianhua; Wang, Xiaobo; Wang, Yajie; Wu, Chenchen; Shi, Mengya; Jiang, Hu‐Lin; Wu, Zimei; Liu, Jianping; Zhang, Wenli

doi:10.1016/j.jconrel.2022.09.036

Cited by 14 publications

(9 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ACE2-CS-PRT@PM also had no significant effects on the indexes of coagulation including prothrombin time, activated partial thromboplastin time, thrombin time and fibrinogen level (Figure F–I). In the process of platelet extraction, prostaglandin E1 and EDTA were added to prevent platelet activation; at the same time, platelet membrane was extracted by freeze–thaw method to remove the conglutination particles that may cause coagulation cascade reaction in platelets . Therefore, intravenous injection of ACE2-CS-PRT@PM did not aggregate, lead to thrombosis, or induce coagulation cascade.…”

Section: Resultsmentioning

confidence: 99%

“…In the process of platelet extraction, prostaglandin E1 and EDTA were added to prevent platelet activation; 28 at the same time, platelet membrane was extracted by freeze−thaw method to remove the conglutination particles that may cause coagulation cascade reaction in platelets. 43 Therefore, intravenous injection of ACE2-CS-PRT@PM did not aggregate, lead to thrombosis, or induce coagulation cascade. In addition, ACE2-CS-PRT@PM did not induce the overexpression of ACE2 protein in the liver and kidneys in HPH or normal rats (Figure S4C).…”

Section: T H I S C O N T E N T Imentioning

confidence: 93%

See 1 more Smart Citation

Biomimetic Nanoparticle-Mediated Target Delivery of Hypoxia-Responsive Plasmid of Angiotensin-Converting Enzyme 2 to Reverse Hypoxic Pulmonary Hypertension

et al. 2023

View full text Add to dashboard Cite

Hypoxic pulmonary hypertension (HPH) is characterized by pulmonary vascular sustained constriction and progressive remodeling, which are initiated by hypoxia then with hypoxia-induced additive factors including pulmonary vascular endothelium injury, intrapulmonary angiotension system imbalance, and inflammation. Now HPH is still an intractable disease lacking effective treatments. Gene therapy has a massive potential for HPH but is hindered by a lack of efficient targeted delivery and hypoxia-responsive regulation systems for transgenes. Herein, we constructed the hypoxia-responsive plasmid of angiotensin-converting enzyme 2 (ACE2) with endothelial-specific promoter Tie2 and a hypoxia response element and next prepared its biomimetic nanoparticle delivery system, named ACE2-CS-PRT@PM, by encapsulating the plasmid of ACE2 with protamine and chondroitin sulfate as the core then coated it with a platelet membrane as a shell for targeting the injured pulmonary vascular endothelium. ACE2-CS-PRT@PM has a 194.3 nm diameter with a platelet membrane-coating core–shell structure and a negatively charged surface, and it exhibits higher delivery efficiency targeting to pulmonary vascular endothelium and hypoxia-responsive overexpression of ACE2 in endothelial cells in a hypoxia environment. In vitro, ACE2-CS-PRT@PM significantly inhibited the hypoxia-induced proliferation of pulmonary smooth muscle cells. In vivo, ACE2-CS-PRT@PM potently ameliorated the hemodynamic dysfunction and morphological abnormality and largely reversed HPH via inhibiting the hypoxic proliferation of pulmonary artery smooth muscle cells, reducing pulmonary vascular remodeling, restoring balance to the intrapulmonary angiotension system, and improving the inflammatory microenvironment without any detectable toxicity. Therefore, ACE2-CS-PRT@PM is promising for the targeted gene therapy of HPH.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: T H I S C O N T E N T Imentioning

confidence: 93%

Biomimetic Nanoparticle-Mediated Target Delivery of Hypoxia-Responsive Plasmid of Angiotensin-Converting Enzyme 2 to Reverse Hypoxic Pulmonary Hypertension

et al. 2023

View full text Add to dashboard Cite

show abstract

“…[45] Therefore, the construction of a sizeadapting drug carrier according to the specificity of TME is a promising strategy. Recently, Zou et al [46] developed a micronanoscale switchable DDS that can regulate the carrier size in delivery. Hollow gold nanoparticles are coated with platelet membrane micro-scale carrier, improving the targeting efficiency of the tumor.…”

Section: Dynamic Assembly/disassembly-controlled Drug Releasementioning

confidence: 99%

“…Recently, Zou et al. [ 46 ] developed a micro‐nanoscale switchable DDS that can regulate the carrier size in delivery. Hollow gold nanoparticles are coated with platelet membrane micro‐scale carrier, improving the targeting efficiency of the tumor.…”

Section: Interactions and Responsive Release Mechanismmentioning

confidence: 99%

“…Organic and inorganic hybrid hollow silica with ultra-thin shells can also achieve deformation through the swelling pH polypeptide polymer Not mentioned [44] pH PG@HGNs Not mentioned [46] Ultrasound liposomal nanodroplet Hydrophobic [23] Solvent activation pH BG-HA@CS Electrostatic interaction and hydrogen bond [49] pH Ce Physical adsorption [50] Not mentioned PMO Hydrophobic van der Waals forces [47] Chemical ond pH G-AuNPs-PEG Hydrazone bonds [34] pH Fe 3 O 4 @mSiO 2 @P2 Hydrophilic interaction hydrogen bond [52] pH MSN Amide bond physical adsorption [53] pH strategy of organic groups. Teng et al [47] fabricated hollow periodic mesoporous organosilicon (PMO) equipped with tunable shell thickness and low Young's modulus, thereby showing a swellability property in organic solvents.…”

Section: Solvent Activation-controlled Drug Releasementioning

confidence: 99%

See 1 more Smart Citation

Response and Regulation of the Microenvironment Based on Hollow Structured Drug Delivery Systems

Zhao

Wei

Xiong

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

Hollow structured materials with easily modifiable surfaces and enclosed interior spaces have emerged as the most promising candidates in drug delivery systems (DDS). With various functional components and inspiring cavities for creative reinvention, the response and regulation of the external and internal microenvironment of hollow structures enable their ideal drug delivery capabilities by improving drug aggregation in targeted sites and maintaining plasma concentrations at the optimal therapeutic ranges. This review begins with an in-depth explanation of the interactions and release mechanisms of hollow structure-based DDS, including diffusion, assembly, solvent activation, and chemical control, all of which are of great significance for the design of smart drug carriers. Next, recent advances in external microenvironmentresponsive drug delivery systems are introduced, based on various chemical signals and external field assists. Focusing on the unique view of intra-carrier variability, the strategies for regulating the internal environment are then highlighted, including pH regulation, temperature regulation, and mechanical force regulation. Finally, this review discusses possible challenges and prospects for hollow structure-based, particularly hollow multishelled structures intelligence-responsive drug delivery platforms, providing valuable strategies for the development of the next generation of responsive DDS.

show abstract

Innovative utilization of cell membrane‐coated nanoparticles in precision cancer therapy

He,

Zhang,

She

et al. 2024

Exploration

View full text Add to dashboard Cite

Cell membrane‐coated nanoparticles (CMNPs) have recently emerged as a promising platform for cancer therapy. By encapsulating therapeutic agents within a cell membrane‐derived coating, these nanoparticles combine the advantages of synthetic nanoparticles and natural cell membranes. This review provides a comprehensive overview of the recent advancements in utilizing CMNPs as effective drug delivery vehicles for cancer therapy. The synthesis and fabrication methods of CMNPs are comprehensively discussed. Various techniques, such as extrusion, sonication, and self‐assembly, are employed to coat synthetic nanoparticles with cell membranes derived from different cell types. The cell membrane coating enables biocompatibility, reducing the risk of an immune response and enhancing the stability of the nanoparticles in the bloodstream. Moreover, functionalization strategies for CMNPs, primarily chemical modification, genetic engineering, and external stimuli, are highlighted. The presence of specific cell surface markers on the coated membrane allows targeted drug delivery to cancer cells and maximizes therapeutic efficacy. Preclinical studies utilizing CMNPs for cancer therapy demonstrated the successful delivery of various therapeutic agents, such as chemotherapeutic drugs, nucleic acids, and immunotherapeutic agents, using CMNPs. Furthermore, the article explores the future directions and challenges of this technology while offering insights into its clinical potential.

show abstract

Glycoprotein Ib-regulated micro platelet ghost for biosafe distribution and photothermal oncotherapy

Cited by 14 publications

References 47 publications

Biomimetic Nanoparticle-Mediated Target Delivery of Hypoxia-Responsive Plasmid of Angiotensin-Converting Enzyme 2 to Reverse Hypoxic Pulmonary Hypertension

Biomimetic Nanoparticle-Mediated Target Delivery of Hypoxia-Responsive Plasmid of Angiotensin-Converting Enzyme 2 to Reverse Hypoxic Pulmonary Hypertension

Response and Regulation of the Microenvironment Based on Hollow Structured Drug Delivery Systems

Innovative utilization of cell membrane‐coated nanoparticles in precision cancer therapy

Contact Info

Product

Resources

About